Advertisements


Alnylam"s LDL-Lowering Drug Positive in Phase II Study

Alnylam Pharmaceuticals, Inc. (ALNY) and its partner T.....»»

Category: topSource: zacksMar 20th, 2017

Alnylam"s LDL-Lowering Drug Positive in Phase II Study

Alnylam Pharmaceuticals, Inc. (ALNY) and its partner T.....»»

Category: topSource: zacksMar 20th, 2017

The Medicines Co LDL-Lowering Drug Positive in Phase II

The Medicines Company (MDCO) announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for .....»»

Category: topSource: zacksJan 9th, 2017

Ultragenyx"s Hypophosphatemia Drug Succeeds in Phase III

Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Hakko Kirin Co., Ltd announced positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked.....»»

Category: topSource: zacksApr 19th, 2017

Roche"s Hemophilia A Drug Positive in Second Phase III Study

Zacks.....»»

Category: topSource: redinewsApr 18th, 2017

Roche"s Hemophilia A Drug Positive in Second Phase III Study

Roche Holding AG's (RHHBY) unit, Genentech, announced positive interim results from the Phase III HAVEN 2 study evaluating its pipeline candidate emicizumab prophylaxis. Roche H.....»»

Category: topSource: zacksApr 17th, 2017

Ultragenyx"s (RARE) XLH Drug Positive in Phase II Study

Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese .....»»

Category: topSource: zacksApr 10th, 2017

Roche Announces Positive Data on Lung Cancer Drug Alecensa

Roche Holdings AG (RHHBY) recently announced encouraging results from the phase III study, ALUR on lung cancer drug Alecensa. Roche Holdings AG RHHBY recently announced encouraging results from the phase III study, ALUR on l.....»»

Category: topSource: zacksApr 5th, 2017

Nektar"s Pain Drug Positive in Phase III Study; Shares Gain

Nektar Therapeutics??? (NKTR) shares surged 42.6% after the company announced positive results from a phase III efficacy study evaluating its investigational candidate, NKTR-181, in patients with moderate to severe chro.....»»

Category: topSource: zacksMar 21st, 2017

AstraZeneca"s Cancer Drug Lynparza Positive in Phase III

AstraZeneca plc (AZN) announced positive results from phase III SOLO-2 study which support the potential benefit of marketed drug Lynparza (olap.....»»

Category: topSource: zacksMar 15th, 2017

GlaxoSmithKline"s Nucala Positive in Label Expansion Study

GlaxoSmithKline plc. (GSK) announced that a phase IIIb study evaluating its respiratory drug Nucala (mepolizumab) met all its primary and secondary endpoints. GlaxoSmithKline plc.  GSK announced that a phase IIIb study ev.....»»

Category: topSource: zacksMar 7th, 2017

Synergy Reports Positive Top-Line Phase III Data on IBS Drug

Synergy Pharmaceuticals announced positive top-line data from a pivotal phase III study evaluating the efficacy and safety of its investigational drug, plecanatide, for the.....»»

Category: topSource: zacksDec 27th, 2016

Roche (RHHBY) Hemophilia A Drug Positive in Phase III

Roche (RHHBY) announced that the phase III study, HAVEN 1, met its primar.....»»

Category: topSource: zacksDec 23rd, 2016

GlaxoSmithKline PLC (ADR) (GSK) Phase 3 Trials Looks Positive: Will Gilead Sciences, Inc. (GILD) Endure?

Efforts by GlaxoSmithKline plc (ADR) (NYSE:GSK) in carrying out a large study on its new HIV drug are yielding positive results. The Phase II.....»»

Category: topSource: insidermonkeyDec 21st, 2016

Novartis Offers Positive Data on Breast Cancer Drug LEE011

Novartis (NVS) announced results from the phase III MONALEESA-2 study on LEE011 for the treatment of first-line HR+/HER2- advanced breast cancer. Shares of Novartis AG NVS gained 3.2% after the company announced encouraging data from a phase II.....»»

Category: topSource: zacksDec 12th, 2016

AstraZeneca (AZN) Presents Tagrisso Data at Medical Meeting

AstraZeneca plc (AZN) presented positive data from a randomized phase III study (AURA3) on its lung cancer drug Tagrisso at a lung cancer conference in Vienna, Austria. AstraZeneca plc AZN presented positive data from a randomized phase III st.....»»

Category: topSource: zacksDec 7th, 2016

Juno Reports Positive Phase I Study Data on Lymphoma Drug

Zacks.....»»

Category: topSource: redinewsDec 6th, 2016

Juno Reports Positive Phase I Study Data on Lymphoma Drug

Juno Therapeutics, Inc. (JUNO) announced encouraging preliminary clinical data from a phase I study (TRANSCEND) on its lead pipeline candidate, JCAR017, for the treatment of patients non-Hodgkin lymphoma (NHL). Juno Therapeutics, Inc. JUNO ann.....»»

Category: topSource: zacksDec 6th, 2016

Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug

Pfizer Inc. (PFE) announced positive top-line results from a phase III study evaluating its marketed drug, Lyrica (pregabalin), as adjunctive therapy for the treatment of pediatric patients suffering from epilepsy with partial-onset seizures. P.....»»

Category: topSource: zacksDec 2nd, 2016

Novartis/Amgen Migraine Drug Positive in Phase III Study

Novartis (NVS) and Amgen (AMGN) migraine treatment AMG 334 hit the primary endpoint in the second phase III episodic migraine study. Novartis AG NVS and partner Amgen Inc. AMGN announced positive top-line data from the second pivotal phase III .....»»

Category: topSource: zacksNov 18th, 2016

Pfizer (PFE) Ibrance Positive in Phase III Breast Cancer Study

Pfizer Inc PFE announced that detailed results of phase III PALOMA 2 study evaluating the combination of its breast cancer drug Ibrance palbociclib and Novartis AG s NVS Femara letrozole for the treatment of first line ER HER2 metastatic breast cancer wer.....»»

Category: futuresSource: nasdaqNov 18th, 2016